Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
March 09 2018 - 7:05AM
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants – SNOAW) today
announced that Jim Schutz, Sonoma CEO, will be a featured presenter
at the Roth Capital Partners 30th Annual Growth Stock Conference on
Tuesday, March 13, 2018 at 3:00 pm PDT in yellow salon 6 at the
Ritz-Carlton in Laguna Niguel, California.
Mr. Schutz will provide an overview of the company’s business
model and growth strategy and will be available for one-on-one
meetings. Interested investors may request a meeting time via
oneononerequests@roth.com, or contacting Bob Miller of Sonoma
Pharmaceuticals either by calling 925-787-6218 or emailing
bmiller@sonomapharma.com.
About Sonoma Pharmaceuticals Sonoma
Pharmaceuticals is a specialty pharmaceutical company that develops
and markets solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals® is a registered trademark of Sonoma
Pharmaceuticals, Inc. All other trademarks and service marks are
the property of their respective owners.
Media and Investor
Contact:
Sonoma Pharmaceuticals,
Inc.
Dan McFaddenVP of Public and Investor Relations(425)
753-2105dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Sep 2023 to Sep 2024